- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04736485
Perioperative Treatment in Resectable Gastric Cancer With Spartalizumab (PDR001) in Combination With Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel (FLOT) (GASPAR)
December 22, 2022 updated by: Centre Francois Baclesse
Perioperative Treatment in Resectable Gastric Cancer With Spartalizumab (PDR001) in Combination With Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel (FLOT): A Phase II Study (GASPAR)
Multicenter, open-label, non randomized, phase 2 trial in resectable gastric or gastroesophageal junction adenocarcinoma: Perioperative Treatment by Spartalizumab (PDR001) in Combination with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT)
Study Overview
Status
Active, not recruiting
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
67
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Besançon, France
- CHU Besançon
-
Caen, France
- Centre Francois Baclesse
-
Dijon, France
- Centre Georges Francois Leclerc
-
Lille, France
- CHRU Lille
-
Marseille, France
- APHM Marseille
-
Montpellier, France
- Institut Régional Cancer
-
Paris, France
- Institut Mutualiste Montsouris
-
Paris, France
- APHP St Louis
-
Poitiers, France
- CHU Poitiers
-
Reims, France
- CHU Robert Debré
-
Rennes, France
- Centre Eugene Marquis
-
Saint-Herblain, France
- ICO St Herblain
-
Saint-Malo, France
- Ch St Malo
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age ≥ 18 years
- Untreated localized gastric or GEJ adenocarcinoma considered resectable (clinical stage ≥cT2 and/or cN+ and no metastasis)
- Histologically confirmed adenocarcinoma
- ECOG performance status score of 0 or 1
- Tumor tissue must be provided for biomarker analyses (fresh or archival with an FFPE tissue block)
- All subjects must consent to allow the acquisition of blood samples for performance of correlative studies
Screening laboratory values must meet the following criteria:
- WBC ≥ 2000/ mm³
- Neutrophils ≥ 1500/ mm³
- Platelets ≥ 100 000/ mm³
- Hemoglobin ≥ 9.0 g/dL
- Bilirubin ≤ 1.5 x ULN, AST and ALT ≤ 3 x ULN
- Measured or calculated creatinine ≥ 50 ml/min clearance (CrCl) (using the Cockcroft-Gault formula)
- Potassium ≥ LLN
- Magnesium ≥ LLN
- Calcium ≥ LLN
- Female subject of childbearing potential must have a negative urine or serum pregnancy test within 72h before study start
- Subject in reproductive age must be willing to use adequate contraception during the study and at least 9 months in men and 12 months in women after the last dose of investigational drug. In addition, given the toxicities observed on the male reproductive system, a conservation of gametes will be proposed for men, as usually in routine practice
- Subject affiliated to a social security regimen
- Patient has signed informed consents obtained before any trial related activities and according to local guidelines
Exclusion Criteria:
Subject with any distant metastasis
- Subject with no recovering from the effects of major surgery or significant traumatic injury within 14 days before inclusion
- Documented significant cardiovascular disease within the past 6 months before the first dose of study treatment, including: history of congestive heart failure (defined as NYHA III or IV), myocardial infarction, unstable angina, coronary angioplasty, coronary stenting, coronary artery bypass graft, cerebrovascular accident or hypertensive crisis
- History of anterior organ transplant, including stem cell allograft
- Pneumonitis or interstitial lung disease
- History of other malignancy within the previous 3 years (except for appropriately treated in-situ cervix carcinoma and non-melanoma skin carcinoma)
- Subject with active, known, or suspected autoimmune disease
- Subject with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of start of study treatment GASPAR Protocol - EUDRACT number: 2020-004497-21 - version 1.3 / 2021-01-18 Page 8 sur 44
- Known history of HIV or HBV infection
- Known active HCV infection
- Known history of active tuberculosis
- Vaccination with live vaccine within 30 days before the first dose of study treatment
- Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2 or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
- Recent or concomitant treatment with brivudine (herpes virostatic)
- Prior anticancer therapy for the current malignancy
- Known hypersensitivity to any of the study drugs or their excipients
- Chronic inflammable gastro-intestinal disease
- Uracilemia ≥ 16 ng/ml
- QT/QTc > 450 msec for men and > 470 msec for women
- Peripheral neuropathy ≥ Grade II
- Uncontrolled diabetes
- Active infection requiring systemic therapy
- Participation in another therapeutic clinical study
- Patient deprived of liberty or placed under the authority of a tutor
- Patient assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: FLOT regimen plus Spartalizumab
Standard FLOT regimen
with Spartalizumab PDR001 Patients will received the fixed dose of 400 mg per IV infusion on D1 every four weeks (q4w) for 2 pre-operative cycles (8 weeks) and 2 post-operative cycles (8 weeks) |
FLOT + Spartalizumab
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pathologic response after pre-operative treatment
Time Frame: At surgery, an average 3 months after treatment initiation
|
Proportion of patients with pCR (pathologic complete response) in the primary tumour defined as: no tumour residue found in the tissue collected during the surgery evaluated by the pathologist
|
At surgery, an average 3 months after treatment initiation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluate the impact of perioperative treatment on disease-free survival
Time Frame: Through study completion, an average of 5 follow-up year
|
Disease-free survival (DFS) defined as time between inclusion and first disease progression
|
Through study completion, an average of 5 follow-up year
|
Evaluate the impact of perioperative treatment on overall survival
Time Frame: Up to death
|
Overall survival (OS) defined as the time between inclusion and death whatever cause;
|
Up to death
|
The correlation between pathologic Complete response and survival outcomes (disease-free and overall survival)
Time Frame: At surgery, an average 3 months after treatment initiation
|
Proportion of patients with margin-free resection (R0), defined as a microscopically margin-negative resection, in which no gross or microscopic tumor remains in the primary tumor bed
|
At surgery, an average 3 months after treatment initiation
|
Treatment-Related Adverse Events
Time Frame: Toxicities occurring up to 1 month after the end of treatment
|
Type, grade and number of Adverse Events as Assessed by CTCAE v5.0
|
Toxicities occurring up to 1 month after the end of treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 28, 2021
Primary Completion (Anticipated)
March 1, 2024
Study Completion (Anticipated)
March 1, 2027
Study Registration Dates
First Submitted
January 26, 2021
First Submitted That Met QC Criteria
January 29, 2021
First Posted (Actual)
February 3, 2021
Study Record Updates
Last Update Posted (Actual)
December 23, 2022
Last Update Submitted That Met QC Criteria
December 22, 2022
Last Verified
December 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2020-004497-21
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Undecided
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Resectable Carcinoma
-
Assiut UniversityUnknownPeriampullary Carcinoma ResectableEgypt
-
Xuzhou Medical UniversityThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical...UnknownPancreaticoduodenectomy | Periampullary Carcinoma ResectableChina
-
National Cancer Institute (NCI)RecruitingPancreatic Acinar Cell Carcinoma | Pancreatic Adenosquamous Carcinoma | Pancreatic Squamous Cell Carcinoma | Resectable Pancreatic Acinar Cell Carcinoma | Resectable Pancreatic Adenocarcinoma | Resectable Pancreatic Adenosquamous Carcinoma | Resectable Pancreatic CarcinomaUnited States
-
Lawson Health Research InstituteLondon Health Sciences FoundationNot yet recruitingBorderline Resectable Pancreatic Adenocarcinoma | Resectable Pancreatic Adenocarcinoma
-
PsiOxus Therapeutics LtdCompletedResectable Colon Cancer | Resectable Non-small Cell Lung Cancer | Resectable Bladder Cancer | Resectable Renal Cell CarcinomaSpain
-
Xiangya Hospital of Central South UniversityRecruitingResectable/Potentially Resectable NSCLCChina
-
Omega TherapeuticsRecruitingHepatocellular Carcinoma | Solid Tumor | Liver Cancer | Hepatocellular Carcinoma Non-resectable | Hepatocellular Cancer | Hepatocellular Carcinoma Recurrent | Liver, Cancer of, Non-ResectableUnited States, Hong Kong, Korea, Republic of, Singapore, Taiwan
-
Mansoura UniversityCompletedPeriampullary Carcinoma ResectableEgypt
-
Beijing 302 HospitalNot yet recruitingHepatocellular Carcinoma Non-resectable | Conversion
-
Jonsson Comprehensive Cancer CenterBristol-Myers Squibb; NovoCure Ltd.RecruitingBorderline Resectable Pancreatic Adenocarcinoma | Resectable Pancreatic Ductal AdenocarcinomaUnited States
Clinical Trials on perioperative treatment
-
Sun Yat-sen UniversityRecruiting
-
Nanjing PLA General HospitalCompletedAbdominal Neoplasms | Surgery | Perioperative Care | Immunization
-
Nanjing Children's HospitalRecruitingInfant ALL | Enhanced Recovery After Surgery | CholangiectasisChina
-
Thammasat UniversityBoontanapibul, Krit, M.D.Completed
-
Zhejiang UniversityCompletedQuality of Life | Complications | Adverse Drug Event | Length of Stay | Hospital CostsChina
-
Centre Hospitalier Universitaire, AmiensCompleted
-
Vanderbilt University Medical CenterEdwards LifesciencesCompletedColorectal Surgery | Perioperative Care | Quality Improvement | ERASUnited States
-
Vrije Universiteit BrusselUniversitair Ziekenhuis Brussel; Research Foundation FlandersTerminated
-
Diskapi Teaching and Research HospitalHacettepe University; Gazi University; Baskent University; Marmara University; Yuzuncu... and other collaboratorsCompleted
-
Ain Shams UniversityCompletedCongenital Heart DiseaseEgypt